HDFC Securities has come out with its second quarter (July-September’ 18) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Divis Labs to report net profit at Rs. 290 crore up 45.7% year-on-year (up 19.4% quarter-on-quarter).
Net Sales are expected to increase by 15 percent Y-o-Y (up 2.9 percent Q-o-Q) to Rs. 1,020 crore, according to HDFC Securities.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 37.3 percent Y-o-Y (up 8.2 percent Q-o-Q) to Rs. 380 crore.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
